Ethyl chromone compound as well as preparation method and application thereof
Through the hydrogen bonding complex of ethylchromosterone compounds and 3CL hydrolase, the antigen drift and cytotoxicity problems in anti-CoV drugs were solved, and the stable inhibition and high safety of 3CL hydrolase were achieved.
Patent Information
- Application Number
- CN202310594211.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-24
- Publication Date
- 2024-11-26
AI Technical Summary
The existing anti-coronavirus drugs cause antigen drift due to nucleic acid sequence mutations, affecting the effectiveness of the vaccine. In addition, 3CL hydrolase target inhibitors are prone to mutations to reduce their efficacy, and are highly cytotoxic to the human body, posing safety hazards.
Develop an ethylchromosteroid compound, which forms a stable hydrogen bond complex with 3CL hydrolase, uses the structural characteristics of sugar ring and amino acid residues Thr190 and Arg188 to significantly inhibit the activity of 3CL hydrolase, and is used to prepare anti-Coronavirus drugs. .
This compound can stably bind 3CL hydrolase, significantly inhibit its activity, has excellent anti-coronavirus effect, and is highly safe. It is suitable for the preparation of anti-SARS-CoV-2 drugs, providing new active ingredients to deal with viral mutations.
Smart Images

Figure CN119019484A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of chemical medicines, and specifically relates to an ethyl chromone compound and a preparation method and application thereof. Background Art
[0002] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the main pathogen that causes the novel coronavirus (COVID-19). It is the third coronavirus with high pathogenicity to humans after SARS-CoV and MERS-CoV. SARS-CoV-2 belongs to the β-genus virus of the Coronaviridae subfamily, Coronavirinae, and the nucleic acid sequence variation of the virus may lead to antigenic drift, thereby allowing the virus to evade the host's immune response and affect the efficacy of the vaccine.
[0003] SARS-CoV-2 is an enveloped beta coronavirus with a large positive-strand RNA genome. 3CL hydrolase is the main protease that cleaves and processes RNA encoded in SARS-CoV-2 itself, and is an indispensable proteolytic enzyme in the replication process of SARS-CoV-2. The cleavage site of 3CL hydrolase is highly conserved in coronaviruses, and it is not easy to have mutations that reduce the efficacy of targeted 3CL hydrolase inhibitors; at the same time, 3CL hydrolase has low homology with human proteases, and its inhibitors have no cytotoxicity and reproductive toxicity to humans, and have high safety. Therefore, 3CL hydrolase inhibitors have become the optimal target for small molecule drugs against the new coronavirus, and obtaining more compounds that can be used to inhibit the activity of 3CL hydrolases will be conducive to the development of anti-SARS-CoV-2 drugs and the treatment of diseases caused by it. Summary of the invention
[0004] In response to the above problems, the present invention provides an ethyl chromone compound and a preparation method and application thereof. The compound can stably bind to the 3CL hydrolase target, has significant inhibitory activity on 3CL hydrolase, and can be used to prepare drugs against the new coronavirus.
[0005] In order to achieve the above-mentioned purpose of the invention, the embodiment of the present invention adopts the following technical solutions:
[0006] In a first aspect, the present invention provides an ethyl chromone compound, the structural formula of which is shown in Formula I:
[0007]
[0008] Molecular dynamics simulation shows that the above-mentioned ethyl chromone compounds provided by the present invention can form a stable complex with 3CL hydrolase through hydrogen bonds, and the structure of the sugar ring in the compound and the amino acid residues Thr190 and Arg188 play an important role in the formation of hydrogen bonds. The stability of the complex is comparable to other current drugs that work by inhibiting 3CL hydrolases. In addition, the compound can form a stable interaction with the binding pocket of 3CL hydrolase and stabilize the amino acid residues therein. Activity evaluation experiments have found that the inhibitory activity of the compound for 3CL hydrolase is superior to that of other compounds with similar structures.
[0009] Therefore, the ethyl chromone compound provided by the present invention can be used to prepare anti-SARS-CoV-2 drugs. The compound is a new compound that has not been reported yet, and provides a new active ingredient for the design of anti-SARS-CoV-2 drugs.
[0010] In a second aspect, the present invention also provides a method for preparing the above-mentioned ethyl chromone compounds, comprising the following steps:
[0011] Step A, extracting the Rhizoma Cynomorii with water, adding ethanol to the obtained water extract, separating the supernatant after static precipitation, removing alcohol from the supernatant, extracting with ethyl acetate and n-butanol, and collecting the aqueous phase;
[0012] Step B, separating the aqueous phase by column chromatography using a macroporous resin column: eluting with water and 5-95% v / v ethanol in sequence, collecting the eluate obtained by eluting with 5-95% v / v ethanol, and concentrating it into a dry paste to obtain a first dry paste;
[0013] Step C, dissolving the first dry paste with an organic solvent, and separating it by column chromatography using a silica gel column: eluting with ethyl acetate, ethanol or a mixture of the two, collecting the obtained eluate, and concentrating it into a dry paste to obtain a second dry paste;
[0014] Step D: Separate the second dry paste using reverse medium pressure preparative chromatography using reverse phase silica gel: elute with 5-15% v / v methanol, 20-30% v / v methanol, and 35-50% v / v methanol in sequence, collect the eluate obtained by eluting with 35-50% v / v methanol, and concentrate to obtain a crude extract containing the ethyl chromone compounds.
[0015] The invention can obtain a crude extract containing the ethyl chromone compounds by extracting the radix cyrtones with water and precipitating them with alcohol, extracting them with ethyl acetate and n-butanol, and then gradually separating the extracts with the above separation process.
[0016] In combination with the first aspect, in steps B, C, and D, the amount of each eluent used can be selected to be 1 to 10 column volumes.
[0017] In combination with the first aspect, the concentration of ethanol in step B is preferably 20% v / v. When elution is performed with ethanol at this concentration, the amount of the eluent used can be 5 column volumes.
[0018] In combination with the first aspect, in step B, the macroporous resin in the macroporous resin column may be AB-8 resin.
[0019] In combination with the first aspect, the organic solvent used to dissolve the first dry paste in step C can be selected from methanol, dichloromethane or a mixture of the two. After the first dry paste is dissolved in the organic solvent, it is mixed with 200-300 mesh silica gel at a mass ratio of 1:3-1, and then the solvent is evaporated to dryness, and added to a silica gel column filled with 200-300 mesh silica gel (equivalent to 5-50 times the weight of the dry paste), and column chromatography separation can be performed.
[0020] In combination with the first aspect, step C preferably uses ethyl acetate for elution, then ethyl acetate-ethanol with a volume ratio of 9:1, and then ethyl acetate-ethanol with a volume ratio of 8:2, and the eluate obtained by eluting with ethyl acetate-ethanol with a volume ratio of 8:2 is collected and concentrated into a dry paste to obtain a second dry paste. When eluting with this operation, the amount of ethyl acetate and ethyl acetate-ethanol can be selected to be 5 column volumes.
[0021] In combination with the first aspect, the preparation method further comprises dissolving the crude extract with a methanol aqueous solution, separating by semi-preparative high performance liquid chromatography, wherein the mobile phase of the semi-preparative high performance liquid chromatography is 5% to 95% v / v methanol aqueous solution-0 to 0.5% v / v formic acid aqueous solution in a volume ratio of 4.5:5.5, and isocratic elution. The eluted fractions are collected according to the peak time of the compound to obtain the compound monomer.
[0022] The concentration of the methanol aqueous solution for dissolving the crude extract is not limited, as long as it can dissolve the crude extract. Exemplarily, the concentration of the methanol aqueous solution is 45-55% v / v.
[0023] Preferably, the chromatographic column of the semi-preparative high performance liquid chromatography is octadecyl bonded silica gel, preferably Waters Xterra ODB, with specifications of 19×250 mm, 10 μm.
[0024] Preferably, the column temperature of the semi-preparative HPLC is 25-35°C, more preferably 30°C.
[0025] Preferably, the flow rate of the semi-preparative HPLC method is 8 to 12 mL / min, more preferably 10 mL / min.
[0026] In a third aspect, the present invention also provides the use of the above-mentioned ethyl chromone compounds in the preparation of 3CL hydrolase inhibitors.
[0027] In a fourth aspect, the present invention also provides the use of the above-mentioned ethyl chromone compounds in the preparation of anti-coronavirus drugs.
[0028] Through experimental verification, it was found that the compound can stably bind to 3CL hydrolase and has excellent inhibitory activity against 3CL hydrolase, and can produce good anti-coronavirus effects, so it can be used to prepare anti-coronavirus drugs.
[0029] In combination with the fourth aspect, the anti-coronavirus drug is an anti-severe acute respiratory syndrome coronavirus type 2 virus drug. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 is the IR spectrum of compound A in Example 1 of the present invention;
[0031] Figure 2 is the HR-ESI-MS spectrum of compound A in Example 1 of the present invention;
[0032] Figure 3 is the compound A in Example 1 of the present invention 1 H--NMR spectrum;
[0033] Figure 4 is the compound A in Example 1 of the present invention 13 C-NMR spectrum;
[0034] Figure 5 is the HSQC spectrum of compound A in Example 1 of the present invention;
[0035] Figure 6 is the HMBC spectrum of compound A in Example 1 of the present invention;
[0036] Figure 7 is the structure and key HMBC of compound A in Example 1 of the present invention;
[0037] Figure 8 is the fluctuation of the root mean square fluctuation (RMSF) value of the amino backbone atoms in the compound-protein complex in Example 6 of the present invention;
[0038] Fig. 9 This is the last conformation of the complex of compound A and 3CL hydrolase in Example 6 of the present invention after stabilization for 100 nanoseconds in molecular dynamics simulation. DETAILED DESCRIPTION
[0039] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0040] SARS-CoV-2 is the main pathogen that causes COVID-19. The nucleic acid sequence variation of the virus may lead to antigenic drift, thereby allowing the virus to evade the host's immune response and affect the efficacy of the vaccine. The embodiment of the present invention provides an ethyl chromone compound (5,7-dihydroxy-2-ethyl chromone-7-O-β-D-glucuronic acid), the structural formula of which is shown in Formula I:
[0041]
[0042] 3CL hydrolase is an indispensable proteolytic enzyme in the replication process of SARS-CoV-2. Its high conservatism and safety make it the optimal target for small molecule drugs against the new coronavirus. The compound provided by the present invention can form a stable complex with 3CL hydrolase, can form a stable interaction with the binding pocket of 3CL hydrolase, and stabilize the amino acid residues therein. The inhibitory activity of the compound for 3CL hydrolase is superior to that of other compounds with similar structures. Therefore, the compound can play a good role in resisting SARS-CoV-2 and can become a new active ingredient of antiviral drugs.
[0043] The present invention also provides a method for preparing the compound, comprising the following steps:
[0044] Step A, extracting the Rhizoma Cynomorii with water, adding ethanol to the obtained water extract, separating the supernatant after static precipitation, removing alcohol from the supernatant, extracting with ethyl acetate and n-butanol, and collecting the aqueous phase;
[0045] Step B, separating the aqueous phase by column chromatography using a macroporous resin column: eluting with water and 5-95% v / v ethanol in sequence, collecting the eluate obtained by eluting with 5-95% v / v ethanol, and concentrating it into a dry paste to obtain a first dry paste;
[0046] Step C, dissolving the first dry paste with an organic solvent, and separating it by column chromatography using a silica gel column: eluting with ethyl acetate, ethanol or a mixture of the two, collecting the obtained eluate, and concentrating it into a dry paste to obtain a second dry paste;
[0047] Step D: Separate the second dry paste using reverse medium pressure preparative chromatography using reverse phase silica gel: elute with 5-15% v / v methanol, 20-30% v / v methanol, and 35-50% v / v methanol in sequence, collect the eluate obtained by eluting with 35-50% v / v methanol, and concentrate to obtain a crude extract containing the above-mentioned ethyl chromone compounds.
[0048] In the above preparation method, the crude extract obtained in step D is dissolved in methanol aqueous solution and separated by semi-preparative high performance liquid chromatography to obtain the monomer of the compound. The mobile phase preferably uses 5% to 95% v / v methanol aqueous solution-0 to 0.5% v / v formic acid aqueous solution in a volume ratio of 4.5:5.5, and the eluted fraction is collected according to the peak time of the compound. The chromatographic column preferably uses octadecyl bonded silica gel, such as Waters Xterra ODB (19×250mm, 10μm). The column temperature is preferably 25 to 35°C. The flow rate is preferably 8 to 12mL / min.
[0049] In order to obtain a better separation effect and reduce the loss of the target product at the same time, the concentration of ethanol in step B is preferably 20% v / v, and step C is preferably eluted with ethyl acetate first, then eluted with ethyl acetate-ethanol with a volume ratio of 9:1, and then eluted with ethyl acetate-ethanol with a volume ratio of 8:2, and the eluate obtained by eluting with ethyl acetate-ethanol with a volume ratio of 8:2 is collected.
[0050] The scheme of the present invention is described below through specific embodiments.
[0051] Example 1
[0052] This embodiment provides an ethyl chromone compound 5,7-dihydroxy-2-ethyl chromone-7-O-β-D-glucuronic acid (hereinafter referred to as compound A) and a preparation method thereof.
[0053] The preparation method of compound A specifically comprises the following steps:
[0054] 1. Preparation of crude extract
[0055] Step A, add 450L of water to 45kg of Mianma Guanzhong and reflux extract for 3 times, each time for 1 hour. Combine the extracts, concentrate under reduced pressure to a specific gravity of 1.10-1.20, add ethanol to a mass concentration of 80%, stand at 4℃ for 24 hours, filter, and take the supernatant. Concentrate the supernatant under reduced pressure until there is no alcohol taste, add water to make the volume 20L, extract with equal volumes of ethyl acetate and n-butanol three times respectively, and then take the aqueous solution;
[0056] Step B, the aqueous solution was fixed to 180 L, and separated using an AB-8 resin column (resin dosage 90 kg), and the separation process was as follows: washing with 5 BV of water and eluting with 20% v / v ethanol, collecting the 20% v / v ethanol eluate (5 BV), and removing the solvent under reduced pressure to obtain a dry paste (first dry paste);
[0057] Step C. Separate the first dry paste obtained in step B using a silica gel (200-300 mesh) column. The separation process is as follows: dissolve the first dry paste in methanol, mix it with silica gel in a mass ratio of 1:2, then evaporate the solvent to dryness, add it to a silica gel column filled with silica gel (equivalent to 20 times the weight of the dry paste), first elute with 5BV ethyl acetate, then elute with 5BV ethyl acetate-ethanol (9:1, v / v), and then elute with 5BV ethyl acetate-ethanol (8:2, v / v), collect the ethyl acetate-ethanol (8:2, v / v) eluate, remove the solvent under reduced pressure, and obtain a dry paste (the second dry paste).
[0058] Step D: Dissolve the second dry paste obtained in step C with methanol, add an equal amount of reversed-phase silica gel (YMC GEL, ODS-AQ-HG, S-50 μm) and mix the sample. After evaporating the solvent, separate the sample by reversed-phase medium-pressure preparative chromatography (filler: YMC GEL, ODS-AQ-HG, S-50 μm; chromatographic column specification: 49×460 mm), and elute with 10% v / v methanol for 5VB, 25% v / v methanol for 5BV, and 40% v / v methanol for 5BV in sequence. Collect the 40% v / v methanol eluate, and remove the solvent under reduced pressure to obtain a crude extract.
[0059] 2. Monomer preparation
[0060] The crude extract was dissolved in 50% v / v methanol aqueous solution, filtered and injected into Waters 1525 semi-preparative liquid chromatograph. The chromatographic conditions were:
[0061] Chromatographic column model: Waters Xterra ODB (19×250mm, 10μm); mobile phase is 50% v / v methanol aqueous solution-0.2% v / v formic acid aqueous solution (4.5:5.5); flow rate 10mL / min; detection wavelength: 210nm, 240nm; column temperature: 30℃; injection volume: 50μl. The results show that under this chromatographic condition, the chromatographic peak separation is good and can be used for preparation and purification. The peak with a retention time of about 20min (the collection time in this embodiment is 19-21min) was collected, and the solvent was recovered under reduced pressure to obtain 20mg of compound A with a purity of >98%.
[0062] 3. Structural identification of compound A
[0063] The chemical structure of compound A was characterized by infrared spectroscopy (IR), mass spectroscopy (MS) and nuclear magnetic resonance (NMR).
[0064] The test data are as follows: IR (KBr) λ max :3305,2905,1720,1656,1620,1502,1422,1336,1260,1176,1081,939,820,763,678,559cm -1;HR-TOF / MS: m / z 383.0971[M+H] + (The calculated value is 383.0978); 1 H-NMR (600 MHz, DMSO-d4) and 13 C-NMR (150 MHz, DMSO-d4) data are shown in Table 1. 1 H-NMR and 13 The C-NMR signals were completely assigned by a combination of HSQC and HMBC.
[0065] IR spectrum, HR-ESI-MS spectrum, 1 H--NMR spectrum, 13 The C-NMR spectrum, HSQC spectrum and HMBC spectrum are shown in Figure 1 to Figure 6 shown.
[0066] Table 1 Compound A in 1 H-NMR and 13 C-NMR spectral data (DMSO-d6)
[0067]
[0068] 4. Experimental Results
[0069] The obtained compound A is a colorless powder, and its molecular formula is C 17 H 18 O 10 . Infrared spectra show that hydroxyl (3306cm -1 ) and carbonyl (1656, 1621cm -1 ) characteristic bands. The NMR spectrum (Table 1) shows that in δ H There is an anomeric proton at 5.25 (1H, d, J = 7.4 Hz, H-1', with δ C 99.8), in δ H There is an ethyl group at 2.68 (2H, q, J = 7.5 Hz, H-11, with δ C 27.0) and δ H .1.22(3H, t, J = 7.5 Hz, H-12, and δ C 11.1), a hydroxyl proton (OH, brs, C-5) at ΔH 12.83, and an olefinic proton (1H, s, H-3, with δ C 107.2), in δ H 6.44 (1H, brs, H-6, and δ C 99.6) and δ H6.71 (1H, brs, H-8, and ΔC 94.8) with a pair of meta-coupled aromatic protons. C 161.6 (C-5), 99.5 (C-6), 162.9 (C-7), 94.8 (C-8), 157.9 (C-9), 105.7 (C-10) and δ C 173.0(C-2), 107.2(C-3) 13 The C-NMR carbon signal also indicates the presence of an aromatic ring fragment and a pair of olefinic fragments. 13 In the C-NMR spectrum, at δ C There is a keto carbonyl group at 182.5 (C-4) and at δ C There is a carboxyl group at 170.6 (C-6'). H 2.68 (H-11) and δ C 173.0(C-2),δ H 1.22 (H-12) and δ C 11.1(C-11),δ H 1.22 (H-12) and δ C The HMBC correlation between 173.0 (C-2) confirmed the ethyl group was attached to C-7.
[0070] Compound A was hydrolyzed with 5% HCl to obtain a mixture of aglycone and sugar. The sugar in the mixture was further purified by EtOAc extraction to remove the aglycone. After concentration, the sugar was identified by comparison with real D-glucuronic acid by TLC (Merck Silica gel 60F254), the solvent system was EtOAc-MeOH-H2O-AcOH (10:10:5:0.5), and the developer was 10% ethanolic sulfuric acid solution. It was identified that the acid hydrolysis of compound A produced D-glucuronic acid. The configuration of the anomeric carbon of the glucosyl fragment was determined to be β by the J value at C-1′. By δ H 5.25(H-1′) and δ C The HMBC correlation between 162.9 (C-7) determined the position of the glucopyranosyl fragment attached to C-6 of the aglycone.
[0071] Based on these observations, the structure of compound A was identified as 5,7-dihydroxy-2-ethylchromone-7-O-β-D-glucuronide (structure and key HMBC as Figure 7 shown).
[0072] Example 2
[0073] This embodiment provides an ethyl chromone compound 5,7-dihydroxy-2-ethyl chromone-7-O-β-D-glucuronic acid (hereinafter referred to as compound A) and a preparation method thereof.
[0074] The preparation method of compound A specifically comprises the following steps:
[0075] 1. Preparation of crude extract
[0076] Step A, add 450L of water to 45kg of Mianma Guanzhong and reflux extract for 3 times, each time for 1 hour. Combine the extracts, concentrate under reduced pressure to a specific gravity of 1.10-1.20, add ethanol to a mass concentration of 80%, stand at 4℃ for 24 hours, filter, and take the supernatant. Concentrate the supernatant under reduced pressure until there is no alcohol taste, add water to make the volume 20L, extract with equal volumes of ethyl acetate and n-butanol three times respectively, and then take the aqueous solution;
[0077] Step B, the aqueous solution was fixed to 180 L, and separated using an AB-8 resin column (resin dosage 90 kg), and the separation process was as follows: washing with 5 BV of water and eluting with 45% v / v ethanol, collecting the 45% v / v ethanol eluate (5 BV), and removing the solvent under reduced pressure to obtain a dry paste (first dry paste);
[0078] Step C. Separate the first dry paste obtained in step B using a silica gel (200-300 mesh) column. The separation process is as follows: dissolve the first dry paste in methanol, mix it with silica gel in a mass ratio of 1:1.5, evaporate the solvent to dryness, add it to a silica gel column filled with silica gel (equivalent to 35 times the weight of the dry paste), first elute with 5BV of ethyl acetate, then elute with 6BV of ethanol, collect the ethanol eluate, remove the solvent under reduced pressure, and obtain a dry paste (the second dry paste).
[0079] Step D: Dissolve the second dry paste obtained in step C with methanol, add an equal amount of reversed-phase silica gel (YMC GEL, ODS-AQ-HG, S-50 μm) and mix the sample. After evaporating the solvent, separate the sample by reversed-phase medium-pressure preparative chromatography (filler: YMC GEL, ODS-AQ-HG, S-50 μm; chromatographic column specification: 49×460 mm), and elute with 5% v / v methanol 4VB, 25% v / v methanol 5BV, and 45% v / v methanol 5BV in sequence. Collect the 45% v / v methanol eluate, and remove the solvent under reduced pressure to obtain a crude extract.
[0080] 2. Monomer preparation
[0081] The crude extract was dissolved in 55% v / v methanol aqueous solution, filtered and injected into Waters 1525 semi-preparative liquid chromatograph. The chromatographic conditions were:
[0082] Chromatographic column model: Waters Xterra ODB (19×250mm, 10μm); mobile phase is 15% v / v methanol aqueous solution-0.3% v / v formic acid aqueous solution (4.5:5.5); flow rate 10mL / min; detection wavelength: 210nm, 240nm; column temperature: 30℃; injection volume: 50μl. The results show that under this chromatographic condition, the chromatographic peak separation is good and can be used for preparation and purification. The eluent was collected at the peak time of compound A, and the solvent was recovered under reduced pressure to obtain 12mg of compound A with a purity of >98%.
[0083] Example 3
[0084] This embodiment provides an ethyl chromone compound 5,7-dihydroxy-2-ethyl chromone-7-O-β-D-glucuronic acid (hereinafter referred to as compound A) and a preparation method thereof.
[0085] The preparation method of compound A specifically comprises the following steps:
[0086] 1. Preparation of crude extract
[0087] Step A, add 450L of water to 45kg of Mianma Guanzhong and reflux extract for 3 times, each time for 1 hour. Combine the extracts, concentrate under reduced pressure to a specific gravity of 1.10-1.20, add ethanol to a mass concentration of 80%, stand at 4℃ for 24 hours, filter, and take the supernatant. Concentrate the supernatant under reduced pressure until there is no alcohol taste, add water to make the volume 20L, extract with equal volumes of ethyl acetate and n-butanol three times respectively, and then take the aqueous solution;
[0088] Step B, the aqueous solution was fixed to 180 L, and separated using an AB-8 resin column (resin dosage 90 kg), and the separation process was as follows: washing with 5 BV of water and then eluting with 25% v / v ethanol, collecting the 25% v / v ethanol eluate (5 BV), and removing the solvent under reduced pressure to obtain a dry paste (first dry paste);
[0089] Step C. Separate the first dry paste obtained in step B using a silica gel (200-300 mesh) column. The separation process is as follows: dissolve the first dry paste in methanol, mix it with silica gel in a mass ratio of 1:2.5, evaporate the solvent to dryness, add it to a silica gel column filled with silica gel (equivalent to 25 times the weight of the dry paste), first elute with 5BV of ethyl acetate, then elute with 6BV of ethyl acetate-ethanol (8:2, v / v), collect the ethyl acetate-ethanol (8:2, v / v) eluate, remove the solvent under reduced pressure, and obtain a dry paste (the second dry paste).
[0090] Step D: Dissolve the second dry paste obtained in step C with methanol, add an equal amount of reversed-phase silica gel (YMC GEL, ODS-AQ-HG, S-50 μm) and mix the sample. After evaporating the solvent, separate the sample by reversed-phase medium-pressure preparative chromatography (filler: YMC GEL, ODS-AQ-HG, S-50 μm; chromatographic column specification: 49×460 mm), and elute with 10% v / v methanol 5VB, 25% v / v methanol 5BV, and 45% v / v methanol 6BV in sequence. Collect the 45% v / v methanol eluate, and remove the solvent under reduced pressure to obtain a crude extract.
[0091] 2. Monomer preparation
[0092] The crude extract was dissolved in 45% v / v methanol aqueous solution, filtered and injected into Waters 1525 semi-preparative liquid chromatograph. The chromatographic conditions were:
[0093] Chromatographic column model: Waters Xterra ODB (19×250mm, 10μm); mobile phase is 55% v / v methanol aqueous solution-0.1% v / v formic acid aqueous solution (4.5:5.5); flow rate 10mL / min; detection wavelength: 210nm, 240nm; column temperature: 30℃; injection volume: 50μl. The results show that under this chromatographic condition, the chromatographic peak separation is good and can be used for preparation and purification. The eluent was collected at the peak time of compound A, and the solvent was recovered under reduced pressure to obtain 11mg of compound A with a purity of >98%.
[0094] Example 4
[0095] This embodiment provides an ethyl chromone compound 5,7-dihydroxy-2-ethyl chromone-7-O-β-D-glucuronic acid (hereinafter referred to as compound A) and a preparation method thereof.
[0096] The preparation method of compound A specifically comprises the following steps:
[0097] 1. Preparation of crude extract
[0098] Step A, add 45kg of Mianma Guanzhong to 420L of water and reflux extract 3 times, each time for 1 hour. Combine the extracts, concentrate under reduced pressure to a specific gravity of 1.10-1.20, add ethanol to a mass concentration of 80%, stand at 4℃ for 24 hours, filter, and take the supernatant. Concentrate the supernatant under reduced pressure until there is no alcohol taste, add water to make the volume 20L, extract with equal volumes of ethyl acetate and n-butanol three times respectively, and then take the aqueous solution;
[0099] Step B, the aqueous solution was fixed to 190 L, and separated using an AB-8 resin column (resin dosage 90 kg), and the separation process was as follows: washing with 5 BV of water and eluting with 5% v / v ethanol, collecting 5% v / v ethanol eluate (10 BV), and removing the solvent under reduced pressure to obtain a dry paste (first dry paste);
[0100] Step C. Separate the first dry paste obtained in step B using a silica gel (200-300 mesh) column. The separation process is as follows: dissolve the first dry paste in dichloromethane, mix it with silica gel in a mass ratio of 1:1, and then evaporate the solvent to dryness. Add it to a silica gel column filled with silica gel (equivalent to 50 times the weight of the dry paste), elute with 3BV ethyl acetate, and remove the solvent under reduced pressure to obtain a dry paste (the second dry paste).
[0101] Step D: Dissolve the second dry paste obtained in step C with methanol, add an equal amount of reversed-phase silica gel (YMC GEL, ODS-AQ-HG, S-50 μm) and mix the sample. After evaporating the solvent, separate the sample by reversed-phase medium-pressure preparative chromatography (filler: YMC GEL, ODS-AQ-HG, S-50 μm; chromatographic column specification: 49×460 mm), and elute with 5% v / v methanol 8VB, 25% v / v methanol 8BV, and 35% v / v methanol 7BV in sequence. Collect the 35% v / v methanol eluate, and remove the solvent under reduced pressure to obtain a crude extract.
[0102] 2. Monomer preparation
[0103] The crude extract was dissolved in 35% v / v methanol aqueous solution, filtered and injected into Waters 1525 semi-preparative liquid chromatograph. The chromatographic conditions were:
[0104] Chromatographic column model: Waters Xterra ODB (19×250mm, 10μm); mobile phase is 5% v / v methanol aqueous solution-water (4.5:5.5); flow rate 10mL / min; detection wavelength: 210nm, 240nm; column temperature: 30℃; injection volume: 50μl. The results show that under this chromatographic condition, the chromatographic peak separation is good and can be used for preparation and purification. The eluent is collected at the peak time of compound A, and the solvent is recovered under reduced pressure to obtain 7mg of compound A with a purity of >98%.
[0105] Example 5
[0106] This embodiment provides an ethyl chromone compound 5,7-dihydroxy-2-ethyl chromone-7-O-β-D-glucuronic acid (hereinafter referred to as compound A) and a preparation method thereof.
[0107] The preparation method of compound A specifically comprises the following steps:
[0108] 1. Preparation of crude extract
[0109] Step A, add 450L of water to 45kg of Mianma Guanzhong and reflux extract for 3 times, each time for 1 hour. Combine the extracts, concentrate under reduced pressure to a specific gravity of 1.10-1.20, add ethanol to a mass concentration of 85%, stand at 4℃ for 24 hours, filter, and take the supernatant. Concentrate the supernatant under reduced pressure until there is no alcohol taste, add water to make the volume 20L, extract with equal volumes of ethyl acetate and n-butanol three times respectively, and then take the aqueous solution;
[0110] Step B, the aqueous solution was fixed to 160L, and separated using an AB-8 resin column (resin dosage 90kg), and the separation process was as follows: washing with 5BV of water and eluting with 95% v / v ethanol, collecting 95% v / v ethanol eluate (1BV), and removing the solvent under reduced pressure to obtain a dry paste (first dry paste);
[0111] Step C. Separate the first dry paste obtained in step B using a silica gel (200-300 mesh) column. The separation process is as follows: dissolve the first dry paste with methanol-dichloromethane (1:1, v / v), mix it with silica gel in a mass ratio of 1:3, and then evaporate the solvent to dryness, add it to a silica gel column filled with silica gel (equivalent to 5 times the weight of the dry paste), elute with 10BV ethanol, collect the eluate, and remove the solvent under reduced pressure to obtain a dry paste (the second dry paste).
[0112] Step D: Dissolve the second dry paste obtained in step C with methanol, add an equal amount of reversed-phase silica gel (YMC GEL, ODS-AQ-HG, S-50 μm) and mix the sample. After evaporating the solvent, separate the sample by reversed-phase medium-pressure preparative chromatography (filler: YMC GEL, ODS-AQ-HG, S-50 μm; chromatographic column specification: 49×460 mm), and elute with 15% v / v methanol 4VB, 30% v / v methanol 5BV, and 50% v / v methanol 6BV in sequence. Collect the 50% v / v methanol eluate, and remove the solvent under reduced pressure to obtain a crude extract.
[0113] 2. Monomer preparation
[0114] The crude extract was dissolved in 10% v / v methanol aqueous solution, filtered and injected into Waters 1525 semi-preparative liquid chromatograph. The chromatographic conditions were:
[0115] Chromatographic column model: Waters Xterra ODB (19×250mm, 10μm); mobile phase is 85% v / v methanol aqueous solution-0.5% v / v formic acid aqueous solution (4.5:5.5); flow rate 10mL / min; detection wavelength: 210nm, 240nm; column temperature: 30℃; injection volume: 50μl. The results show that under this chromatographic condition, the chromatographic peak separation is good and can be used for preparation and purification. The eluent is collected at the peak time of compound A, and the solvent is recovered under reduced pressure to obtain 5mg of compound A with a purity of >98%.
[0116] Example 6
[0117] In this example, the binding and activity of compound A obtained in Example 1 with 3CL hydrolase were evaluated.
[0118] 1. Activity prediction
[0119] The SDF file of compound A was downloaded from the PubChem database (https: / / pubchem.ncbi.nlm.nih.gov / ) and converted to MOL2 format by Open Babel 2.4.1. The crystal structure of the novel coronavirus (SARS-CoV-2) 3CL hydrolase (PDBID: 7VH8) was downloaded from the PDB database (https: / / www.rcsb.org / ). In addition to the co-crystallized ligand PF-07321332 (nirmatrelvir), three drugs (α-ketoamide, lopinavir, and ritonavir) that have been reported to inhibit 3CL hydrolases were selected as positive controls. The small molecules were energy minimized using PyRx-0.8 software. Ligands and receptors were prepared according to the AutoDock Vina1.1.2 tutorial. For each structure, water molecules were removed, nonpolar hydrogens were added, Gasteiger charges were calculated, and saved in PDBQT format. Generally, the lower the Vina score, the higher the affinity between the ligand and the receptor. The general selection threshold is a binding energy ≤ -5 kcal / mol.Finally, the interaction pattern between compound A and 3CL hydrolase was visualized using Pymol software.
[0120] This example also tests the binding affinity of two other self-isolated compounds b and c that are similar in structure to compound A to 3CL hydrolase.
[0121] The results are shown in Table 2.
[0122] Table 2 Docking scores between each compound and 3CL hydrolase
[0123]
[0124] The binding free energies of the above compounds with the 3CL hydrolase target are all lower than -5.0 kJ / mol (a binding free energy less than -5 kcal / mol is considered to have good binding activity. The lower the binding energy, the more stable the ligand-receptor binding conformation), indicating that the ligand and receptor can bind stably.
[0125] In order to dynamically analyze the interaction mode between the receptor 3CL hydrolase and compound A from the perspective of kinetics and thermodynamics, molecular dynamics simulation was performed using GROMACS 4.5 in this example. Protein topology parameters were obtained from the CHARMM36 force field using the PDB2GMX tool. The electrostatic potential of the inhibitor atomic charge was calculated using the Def2-MTZVP basis set of ORCA, and the RESP charge was obtained by fitting using the program Multiwfn 3.7. The complex was placed in a The dodecahedral TIP3P water box was filled with Na + and Cl - To maintain electroneutrality, energy minimization and pre-equilibration were performed. Finally, molecular dynamics simulations were performed at 300 K for 100 ns with a time interval of 2 fs, and energy and coordinate files were saved every 10 ps.
[0126] The results showed that after 35ns of simulation, the root mean square deviation (RMSD) of all systems was 0.1-0.3nm, the fluctuation range was below 0.1nm, and all reached equilibrium.
[0127] By calculating the root mean square fluctuation (RMSF) of the amino backbone atoms in the molecular dynamics simulation of the small molecule and the receptor protein in the complex, this experiment analyzed the effect of compound A on the fluctuation of each amino acid residue in 3CL hydrolase. The study found that the distribution trend of the RMSF value of the complex formed by compound A and 3CL hydrolase obtained in Example 1 is similar to that of PF-07321332 (e.g. Figure 8 The results show that compound A can form a stable interaction with the binding pocket of 3CL hydrolase and stabilize the amino acid residues therein.
[0128] This experiment extracted the last conformation of the complex after stabilization for 100 nanoseconds in molecular dynamics simulation (e.g. Fig. 9 As shown). In order to explore the important role of key groups or amino acid residues in the molecule in the formation of hydrogen bonds, this experiment summarizes the amino acid residues that form hydrogen bonds between 3CL hydrolase and compound A and compound c, as shown in Table 3. The results show that the interaction between 3CL hydrolase and the co-crystallized molecule PF-07321332 includes not only hydrogen bonds, but also CH bonds, halogen bonds and alkyl bonds. The interaction between the compound and the amino acid residue is mainly hydrogen bonding. The force of hydrogen bonding reduces the binding energy and increases the affinity. Compound A tightly binds to the active site of 3CL hydrolase to form a stable complex, which can effectively prevent the attachment of foreign viruses and the invasion of host cells.
[0129] PF-07321332 formed three hydrogen bonds with the amino acid residues (Asn142, Glu166 and Gln192) of 3CL hydrolase, indicating that these three amino acid residues may be very important in the drug action process. Compared with the cocrystallized molecule PF-07321332, the sugar ring structure in compound A and compound c played a key role in the formation of hydrogen bonds. Glu166 participated in the formation of hydrogen bonds in the stable conformation of compound A, compound c and 3CL hydrolase. This experiment found two new amino acid residues Thr190 and Arg188, both of which played a key role in the formation of stable conformations of compound A and compound c with 3CL hydrolase, indicating that they may also play an important role in the action of antiviral drugs.
[0130] Table 3 Hydrogen bonds between compounds and 3CL hydrolase
[0131]
[0132] 2. Activity evaluation
[0133] 50 μL of compound A, compound B, and compound C stock solutions (all 100 mM) were added to a 384-well plate, and then DMSO was added to dilute the solutions into a series of concentrations, with a total of 10 concentrations. 665 SYSTEMLABCYTE) Transfer 0.2 μL of the diluted solution to a 384-well assay plate, with 2 replicates for each sample. Add 10 μL of 3CL hydrolase (BPSbioscience) working solution to the 384-well plate, centrifuge at 1000 rpm for 1 minute, and incubate at 25°C for 15 minutes. Add 10 μL of substrate working solution and incubate at 25°C for 4 hours. Measure the Ex 350nm and Em 460nm fluorescence signals with a microplate reader. Calculate the enzyme activity inhibition rate according to the following formula.
[0134] Inhibition percentage of compound (%inh) = 100 × (ave high control - cpd (compound) well) / (ave high control - ave low control)
[0135] The results are shown in Table 4.
[0136] Table 4 Activity test results
[0137]
[0138]
[0139] Example 7
[0140] This embodiment provides an anti-severe acute respiratory syndrome coronavirus type 2 virus drug, the active ingredient of the drug is 5,7-dihydroxy-2-ethylchromone-7-O-β-D-glucuronic acid obtained in Example 1.
[0141] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modification, equivalent substitution or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. An ethyl chromone compound, It is characterized in that Its structural formula is shown in Formula I:
2. A method for preparing the ethyl chromone compound according to claim 1, It is characterized in that The following steps are involved: Step A, extracting the Rhizoma Cynomorii with water, adding ethanol to the obtained water extract, separating the supernatant after static precipitation, removing alcohol from the supernatant, extracting with ethyl acetate and n-butanol, and collecting the aqueous phase; Step B, separating the aqueous phase by column chromatography using a macroporous resin column: eluting with water and 5-95% v / v ethanol in sequence, collecting the eluate obtained by eluting with 5-95% v / v ethanol, and concentrating it into a dry paste to obtain a first dry paste; Step C, dissolving the first dry paste with an organic solvent, and separating it by column chromatography using a silica gel column: eluting with ethyl acetate, ethanol or a mixture of the two, collecting the obtained eluate, and concentrating it into a dry paste to obtain a second dry paste; Step D: Separate the second dry paste using reverse medium pressure preparative chromatography using reverse phase silica gel: elute with 5-15% v / v methanol, 20-30% v / v methanol, and 35-50% v / v methanol in sequence, collect the eluate obtained by eluting with 35-50% v / v methanol, and concentrate to obtain a crude extract containing the above-mentioned ethyl chromone compounds.
3. The method for preparing the ethyl chromone compound according to claim 2, It is characterized in that In step B, the amount of the eluent is 5 column volumes; and / or In step C, the amount of the eluent is 5 column volumes; and / or In step D, the amount of the eluent used is 5 column volumes.
4. The method for preparing the ethyl chromone compound according to claim 2, It is characterized in that In step B, the macroporous resin in the macroporous resin column is AB-8 resin.
5. The method for preparing ethyl chromone compounds according to any one of claims 2 to 4, It is characterized in that The preparation method also includes dissolving the crude extract in a methanol-water solution, separating by semi-preparative high performance liquid chromatography, wherein the mobile phase is a 5% to 95% v / v methanol-water solution-0 to 0.5% v / v formic acid-water solution in a volume ratio of 4.5:5.5, and isocratic elution.
6. The method for preparing the ethyl chromone compound according to claim 5, It is characterized in that The chromatographic column of the semi-preparative high performance liquid chromatography is octadecyl bonded silica gel; and / or The column temperature of the semi-preparative HPLC method is 25-35°C; and / or The flow rate of the semi-preparative high performance liquid chromatography is 8 to 12 mL / min.
7. The method for preparing the ethyl chromone compound according to claim 6, It is characterized in that The chromatographic column of the semi-preparative HPLC method is a Waters Xterra ODB, with specifications of 19×250 mm, 10 μm; The column temperature of the semi-preparative HPLC method is 30°C; and / or The flow rate of the semi-preparative HPLC was 10 mL / min.
8. Use of the ethyl chromone compound according to claim 1 in the preparation of 3CL hydrolase inhibitors.
9. Use of the ethyl chromone compounds described in claim 1 in the preparation of anti-coronavirus drugs.
10. The use according to claim 9, It is characterized in that The anti-coronavirus drug is an anti-severe acute respiratory syndrome coronavirus type 2 virus drug.
